Senior Medical Advisor
Tore provides medical expertise in the development of clinical research programs. He has extensive experience of drug development focusing on clinical trials, safety and regulatory interactions.
He is an upper G.I. surgeon by training and was an external advisor to AstraZeneca from 1980 to 2000 where he was closely involved in the development of Losec® and Nexium®. He was also the principal investigator in numerous international clinical trials using acid suppressive therapy. He joined AstraZeneca full-time in 2000 as Global Medical Director.
Tore joined Isofol in mid-2014.View Profile
Dr. Nilsson, MD, PhD, is one of Scandinavia’s leading clinicians in urological oncology. He has served as a Professor of Oncology at the Karolinska Hospital, Stockholm, Sweden and has wide ranging clinical and research experience in the fields of oncology and nuclear medicine. In the industry, Prof. Nilsson has been part of the advisory boards of several leading pharmaceutical companies such as Bayer Healthcare, Janssen, Ipsen, Novartis, AstraZeneca, Pharmacia/Pfizer, Roche and Lilly. He is founder of Dextech Medical (Aktietorget, Stockholm) and is providing scientific and strategic advice as a member of the board of PledPharma (Nasdaq First North), and Spago Nanomedical (Aktietorget, Stockholm).View Profile
Mr Robert Marchesani is currently principal at Proventus Health Solutions, LLC and an adjunct faculty member and executive career mentor at Butler University, Lacy School of Business in Indianapolis, Indiana. At Proventus, he serves as a consultant to oncology companies to incorporate prescriber, patient and payer insights throughout drug development and commercialization. Prior to joining Proventus, Mr. Marchesani spent more than 25 years at Eli Lilly and Company where he led the global branding, marketing and launch of a number of cancer therapeutics including, ALIMTA® (pemetrexed), Gemzar® (gemcitabine) and Verzenio™ (abemaciclib). Mr. Marchesani received his Bachelor of Arts degree in journalism and public relations from Indiana University of Pennsylvania and Masters of Business Administration with a concentration in marketing from the University of Indianapolis.
Robert joined Isofol in november 2018.View Profile